Trial Profile
Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Patients With Metastatic or Unresectable Sarcoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Oct 2023
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Ipilimumab
- Indications Gastrointestinal stromal tumours; Liposarcoma; Malignant fibrous histiocytoma; Osteosarcoma; Soft tissue sarcoma
- Focus Therapeutic Use
- 06 Jun 2023 Status changed from active, no longer recruiting to completed.
- 23 Sep 2022 Planned End Date changed from 10 Aug 2022 to 10 Aug 2023.
- 01 Sep 2021 Planned End Date changed from 15 Jun 2022 to 10 Aug 2022.